Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.
about
Targeting the Hedgehog Pathway in Pediatric MedulloblastomaMolecular classification of gastric cancer: Towards a pathway-driven targeted therapyCooperative integration between HEDGEHOG-GLI signalling and other oncogenic pathways: implications for cancer therapySmoothened variants explain the majority of drug resistance in basal cell carcinomaVismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.Generation of a mouse model of atypical teratoid/rhabdoid tumor of the central nervous system through combined deletion of Snf5 and p53.Diagnostic application of high resolution single nucleotide polymorphism array analysis for children with brain tumorsPediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape.The Ketogenic Diet Does Not Affect Growth of Hedgehog Pathway Medulloblastoma in Mice.RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.Improving the outcome for children with cancer: Development of targeted new agents.Relapsed High-Risk Medulloblastoma: Stable Disease after Two Years of Treatment with Somatostatin Analog - Case Report.Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations.Chemotherapy increases long-term survival in patients with adult medulloblastoma--a literature-based meta-analysis.Pediatric Brain Tumors: Current Knowledge and Therapeutic OpportunitiesCisplatin induces stemness in ovarian cancer.Molecular variants and mutations in medulloblastoma.Targeting hedgehog signaling in myelofibrosis and other hematologic malignanciesTargeted treatment for sonic hedgehog-dependent medulloblastoma.Molecular insights into pediatric brain tumors have the potential to transform therapy.Nestin Mediates Hedgehog Pathway Tumorigenesis.Nanomedicine as an innovative therapeutic strategy for pediatric cancer.Molecular biology of pediatric brain tumors and impact on novel therapies.Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.Medulloblastoma development: tumor biology informs treatment decisionsTargeted approaches to childhood cancer: progress in drug discovery and development.SHH inhibitors for the treatment of medulloblastoma.Physiological, Tumor, and Metastatic Niches: Opportunities and Challenges for Targeting the Tumor Microenvironment.Experimental Therapeutic Trial Design for Pediatric Brain Tumors.p53 and Meduloblastoma.Medulloblastoma: Tumor Biology and Relevance to Treatment and Prognosis Paradigm.Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.Precision medicine in pediatric oncology: Lessons learned and next steps.Hedgehog Signal Transduction: Key Players, Oncogenic Drivers, and Cancer Therapy.A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.Restore the brake on tumor progression.Complete and sustained response of adult medulloblastoma to first-line sonic hedgehog inhibition with vismodegib.Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor.
P2860
Q26777997-CE3B19C6-00AE-4831-8E78-9C08A8B679C5Q26798420-E414D308-3085-4BEE-A221-9226AF2DCFFCQ26865136-0600F2EA-0436-45A8-BBA6-79EED48A7AE0Q27853140-CCA80D79-C645-4271-AB7F-AF3011EE4052Q27853187-E4F7BA4C-11B1-411E-8F3B-D05C3A6F4C34Q30234441-176395F8-38CD-4BE5-A584-32EF4EC206D1Q30671578-A813E393-C5F6-4418-B2D9-D20A33F5467BQ34166553-78B64620-8442-4B6D-83FA-47B6027530B7Q35754390-EACDA044-C9A8-4B1D-9316-3987D4128D21Q35867273-D8F75636-9847-4F7F-A399-D886736DE9E4Q36021289-857D2857-473F-4538-8A8E-BCF131284438Q36238795-316637CC-A536-457B-8926-63CE5F7B7EDDQ36552290-4BB63429-0EA3-47AA-AFE3-27A592A12475Q36600202-21059C4D-3589-4039-9755-A1804E677D8DQ36612342-3256E620-4184-4579-AC01-EE912E928738Q36618254-6B721446-28D3-4316-A456-859B880961E4Q37213305-BFE2F788-0A6E-43EF-9A29-428C9684D4C5Q37327524-B7B38AA2-8AE4-43F4-8501-105A670723C9Q37579203-9EE0AB1A-46EA-4C46-A23C-36ACA9881B10Q38193610-42F5020B-97CE-4FF1-A2DB-DC3BD12F985EQ38222028-2C2D5058-A4C1-4C9C-8047-368244E3990AQ38268366-B449B765-030C-483B-9BAA-B86E23ADA9F1Q38291439-BFB61BCF-4C15-4AC2-8AE3-A32233EADF66Q38359099-017D5CA8-751D-4F1A-87F8-5FB3FFC62299Q38359284-2ABCF93B-9595-48C7-B069-A34FF6B77D8FQ38371672-B2910893-3918-4C43-BEA7-0AE2C70E658EQ38376606-AF890B30-1C69-4003-AD7A-EE29C8A586ABQ38404462-AE2D63F4-415B-49B9-ACE7-B59BB681B9B1Q38509205-1FE316EB-BE22-4117-BD89-4139A2B15514Q38582873-36A3C4D8-C316-4293-80A8-BD2B5030449BQ38583655-90D724AE-F892-4892-82C7-DA112083516DQ38673795-0865E146-3707-47A7-8CE1-FAB4866920D1Q38791824-3C3A144E-E13B-4D81-95DE-CAF454405238Q38802190-7D65D0D3-53A5-4DA5-B0A0-3DC6545F0812Q38810911-382D1E07-C2E4-41DA-9A51-158F059072B4Q38935571-A7AB7DD6-6176-4831-A7D9-CF7329B553D4Q38961012-AA861556-1238-462D-9121-A428065A5007Q39227418-49F1AFF3-C997-4860-B0AF-CF6313129242Q41573477-F29EDC05-325C-4DC0-A52E-CF06C1BB5DACQ42378333-EBAEAE08-054F-43C2-9AA3-A1C6BD3F2F51
P2860
Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase I study of vismodegib in ...... brain tumor consortium study.
@en
Phase I study of vismodegib in ...... brain tumor consortium study.
@nl
type
label
Phase I study of vismodegib in ...... brain tumor consortium study.
@en
Phase I study of vismodegib in ...... brain tumor consortium study.
@nl
prefLabel
Phase I study of vismodegib in ...... brain tumor consortium study.
@en
Phase I study of vismodegib in ...... brain tumor consortium study.
@nl
P2093
P2860
P1476
Phase I study of vismodegib in ...... brain tumor consortium study.
@en
P2093
Amar Gajjar
Clinton F Stewart
Dana Wallace
David W Ellison
James M Boyett
Larry E Kun
Murali Chintagumpala
Naoko Takebe
Richard J Gilbertson
Roger J Packer
P2860
P304
P356
10.1158/1078-0432.CCR-13-1425
P407
P577
2013-09-27T00:00:00Z